Solara Active Pharma Sciences Ltd (SOLARA)

Solara Active Pharma Sciences Ltd is a Public Limited Company incorporated in 2017 with operations in 75 countries across the globe, primarily dealing in APIs and developing 80 commercial APIs predominantly in anthelmintic antimalarias antiinfective neuromuscular insomnia and antipsychotic hyperkalemia segments. The business is spread across North America, Europe, Japan, South Korea, Middle East and North Africa offering a basket of niche and high-value products. The Company has six manufacturing plants in Ambernath, Mangalore, Mysore, Puducherry, Vishakhapatnam and Cuddalore, with a capacity of over 2000 kilo litres and two RD Centres in Chennai and Bangalore. The facilities boast of approvals from USFDA, EDQM, KFDA, EUGMP, WHO Geneva, Cofepris, TGA Australia, and PMDA Japan. In the financial year of 2020-21, the Company achieved a Certificate of Merit from National Safety Council Maharashtra and improved EcoVadis score from 31 to 47, awarded with a bronze medal and also achieved certification for ISO 14001 and ISO 45001 in its Mangalore site. The Company also has two research and development units with 25 products in different stages of development. The Board of Directors approved the Scheme of Amalgamation of Strides Chemicals and three other Transferor Companies with the Company Transferee Company, approved the acquisition of 487000 additional share capital in Sequent Penems Private Limited, and the new Greenfield plant has commenced commercial production in 2021.

Share Price: ₹484.10 per share as on 18 May, 2024 04:01 PM
Market Capitalisation: ₹2,335.68Cr as of today
Revenue: ₹248.73Cr as on December 2023 (Q4 23)
Net Profit: ₹-275.34Cr as on December 2023 (Q4 23)
Listing date: 27 Jun, 2018
Chairperson Name: Aditya Puri